CRISPR Genomic Cure has emerged as a promising technology for repairing DNA at the genomic level. CRISPR therapies hold immense potential for treating various genetic disorders by correcting disease-causing mutations in the genome. They can be designed to target specific parts of the genetic code, allowing permanent and precision editing of DNA sequences. The global CRISPR Genomic Cure Market is estimated to be valued at US$ 1.84 Bn in 2023 and is expected to exhibit a CAGR of 34% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The emergence of rare and complex diseases has provided huge opportunities for CRISPR therapy. According to the Global Genes organization, there are over 7,000 rare diseases impacting over 300 million people worldwide. Existing treatments for many rare diseases are limited. CRISPR holds potential for targeting disease-causing mutations simultaneously and providing permanent cures. Clinical trials are exploring its applications in reducing the risk of blindness, treating blood disorders like sickle cell disease and beta-thalassemia, and curing lung cancer and melanoma. The successful demonstration of CRISPR's capabilities in clinical settings can accelerate its adoption for treating various rare and complex genetic diseases in the coming years.
Segment Analysis
The global Crispr Genomic Cure Market is dominated by the therapeutics segment. Currently gene editing tools such as Crispr are primarily being used for research and drug discovery purposes. Companies are developing Crispr therapeutics to cure genetic disorders caused due to single gene mutations. The therapeutics segment is projected to witness high growth during the forecast period owing to ongoing clinical trials and potential approval of first Crispr based gene therapy drugs.
Key Takeaways
The Global CRISPR Genomic Cure Market Size is expected to witness high growth during the forecast period. Rising prevalence of genetic disorders, advancements in gene editing technologies and increasing focus on developing precision medicines are projected to drive market growth.
Regional analysis: North America currently dominates the global Crispr Genomic Cure market. Presence of major players, rising healthcare expenditure, increasing funding for genomic research are some factors contributing to dominance of North America. Asia Pacific is projected to be the fastest growing regional market during the forecast period owing to growing genomics research, high disease prevalence and improving healthcare infrastructure in countries like China and India.
Key players: Key players operating in the Crispr Genomic Cure market are CRISPR Therapeutics AG, Editas Medicine, Inc., Intellia Therapeutics, Inc., Sangamo Therapeutics, Inc., Beam Therapeutics Inc., Caribou Biosciences, Inc., Mammoth Biosciences, Precision Biosciences, Inc., Synthego Corporation, GenScript Biotech Corporation, Horizon Discovery Group plc, Lonza Group Ltd., Takara Bio Inc., Merck KGaA, Thermo Fisher Scientific Inc. CRISPR Therapeutics and Editas Medicine are among the leading players developing Crispr based therapies for genetic disorders.
For More Insights, Read: https://www.newsstatix.com/crispr-genomic-cure-market-size-share-and-growth-forecast-2023-2030/
Comments
0 comment